Literature DB >> 17382727

Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma.

Carlos Bermejo1, J Erik Busby, Philippe E Spiess, Lior Heller, Lance C Pagliaro, Curtis A Pettaway.   

Abstract

PURPOSE: Combination chemotherapy for advanced penile cancer can produce partial response rates of up to 64%. Complete responses are rare, suggesting a need for adjunct therapies to facilitate cure. We evaluated patients with metastases who underwent surgical consolidation after responding to chemotherapy.
MATERIALS AND METHODS: We reviewed the records of 59 patients with advanced penile carcinoma treated from 1985 to 2000 and identified 10 treated with surgical consolidation after demonstrating a stable, partial or complete response to chemotherapy. Presenting tumor burden included pelvic and inguinal metastases. Surgical outcomes and survival were assessed.
RESULTS: After chemotherapy 4 patients had a complete response, 1 had a partial response and 5 had stable disease. Three major perioperative complications, including postoperative bleeding, an episode of acute renal failure and deep venous thrombosis in 1 patient each, and 4 minor complications, including skin breakdowns in 3 and wound seroma in 1, occurred. Three cases were rendered pN0. All 3 patients received ifosfamide, paclitaxel and cisplatin chemotherapy. Seven patients had 3 or fewer metastatic lymph nodes following surgery, of whom 4 showed no disease and 3 died. All 3 patients with greater than 3 metastatic lymph nodes died. For all patients the 5-year actuarial survival rate was 40% with a median survival of 26 months. Patients with 3 or fewer and greater than 3 positive nodes had a median survival of 48 and 23 months, respectively (p = 0.116).
CONCLUSIONS: Select patients with metastatic penile cancer that shows disease stabilization or a response to chemotherapy should be considered for surgical consolidation to extend survival.

Entities:  

Mesh:

Year:  2007        PMID: 17382727     DOI: 10.1016/j.juro.2006.11.038

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  39 in total

Review 1.  Advanced penile cancer.

Authors:  Jonathan E Heinlen; David D Buethe; Daniel Joseph Culkin
Journal:  Int Urol Nephrol       Date:  2011-08-04       Impact factor: 2.370

2.  Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.

Authors:  Lance C Pagliaro; Dallas L Williams; Danai Daliani; Michael B Williams; William Osai; Michael Kincaid; Sijin Wen; Peter F Thall; Curtis A Pettaway
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

3.  Delivery of chemotherapeutic drugs in tumour cell-derived microparticles.

Authors:  Ke Tang; Yi Zhang; Huafeng Zhang; Pingwei Xu; Jing Liu; Jingwei Ma; Meng Lv; Dapeng Li; Foad Katirai; Guan-Xin Shen; Guimei Zhang; Zuo-Hua Feng; Duyun Ye; Bo Huang
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

4.  Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study.

Authors:  Dominic H Tang; Rosa Djajadiningrat; Gregory Diorio; Juan Chipollini; Zhenjun Ma; Braydon J Schaible; Mario Catanzaro; Dingwei Ye; Yao Zhu; Nicola Nicolai; Simon Horenblas; Peter A S Johnstone; Philippe E Spiess
Journal:  Urol Oncol       Date:  2017-06-27       Impact factor: 3.498

5.  Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).

Authors:  Suzanne Richter; J Dean Ruether; Lori Wood; Christina Canil; Patricia Moretto; Peter Venner; Joel Gingerich; Urban Emmenegger; Andrea Eisen; Pawel Zalewski; Anthony Joshua; Som Dave Mukherjee; Daniel Heng; Piotr Czaykowski; Denis Soulieres; Norman Blais; Ricardo Rendon; Neil Fleshner; Juanita M Crook; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

6.  Contemporary management of penile cancer: greater than 15 year MSKCC experience.

Authors:  Kelvin A Moses; Andrew Winer; John P Sfakianos; Stephen A Poon; Matthew Kent; Melanie Bernstein; Paul Russo; Guido Dalbagni
Journal:  Can J Urol       Date:  2014-04       Impact factor: 1.344

7.  What next? Managing lymph nodes in men with penile cancer.

Authors:  Michael Leveridge; D Robert Siemens; Christopher Morash
Journal:  Can Urol Assoc J       Date:  2008-10       Impact factor: 1.862

8.  [The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics].

Authors:  C Protzel; S Ruppin; S Milerski; K-J Klebingat; O W Hakenberg
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

Review 9.  [Value of targeted therapy for penile cancer].

Authors:  A Heidenreich; D Thüer; D Pfister
Journal:  Urologe A       Date:  2008-10       Impact factor: 0.639

Review 10.  Contemporary inguinal lymph node dissection: minimizing complications.

Authors:  Philippe E Spiess; Mike S Hernandez; Curtis A Pettaway
Journal:  World J Urol       Date:  2008-09-02       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.